Návratnost kapitálu společnosti Albireo Pharma Inc
Jaká je hodnota metriky Návratnost kapitálu společnosti Albireo Pharma Inc?
Hodnota metriky Návratnost kapitálu společnosti Albireo Pharma Inc je -43.59%
Jaká je definice metriky Návratnost kapitálu?
Return on capital employed (ROCE) je finanční ukazatel, který měří rentabilitu společnosti a efektivitu společnosti ve využívání vlastního kapitálu.
Return on capital employed (ROCE) is the total amount of capital that a company has utilized in order to generate profits. It is the sum of shareholders' equity and debt liabilities. It can be simplified as total assets minus current liabilities.
ROCE is especially useful when comparing the performance of companies in capital-intensive sectors. ROCE considers debt and other liabilities as well compared to other fundamentals which only analyze profitability related to a company’s common equity. This provides a better indication of financial performance for companies with significant debt. For a company, the ROCE trend over the years is also an important indicator of performance. In general, investors tend to favor companies with stable and rising ROCE numbers over companies where ROCE is volatile and bounces around from one year to the next.
Instead of using capital employed at an arbitrary point in time, analysts and investors often calculate ROCE based on the average capital employed (ROACE), which takes the average of opening and closing capital employed for the time period.
Návratnost kapitálu společností v sektoru Health Care sektor na NASDAQ ve srovnání se společností Albireo Pharma Inc
Čemu se věnuje společnost Albireo Pharma Inc?
Albireo Pharma is a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat rare pediatric and adult liver diseases, and other adult liver diseases and disorders. Albireo's lead product candidate, odevixibat, is being developed to treat rare pediatric cholestatic liver diseases with Phase 3 pivotal trials in PFIC, Alagille syndrome and biliary atresia. The Company completed IND-enabling studies for new preclinical candidate A3907 this year and plans to advance development in adult liver disease. Albireo was spun out from AstraZeneca in 2008 and is headquartered in Boston, Massachusetts, with its key operating subsidiary in Gothenburg, Sweden. The Boston Business Journal named Albireo one of the 2020 Best Places to Work in Massachusetts for the second consecutive year.
Firmy s metrikou návratnost kapitálu podobnou společnosti Albireo Pharma Inc
- Hodnota metriky Návratnost kapitálu společnosti Apyx Medical je -43.78%
- Hodnota metriky Návratnost kapitálu společnosti HUTCHMED (China) je -43.71%
- Hodnota metriky Návratnost kapitálu společnosti Goodrich Petroleum je -43.68%
- Hodnota metriky Návratnost kapitálu společnosti Stoke Therapeutics je -43.66%
- Hodnota metriky Návratnost kapitálu společnosti Adverum Biotechnologies Inc je -43.65%
- Hodnota metriky Návratnost kapitálu společnosti Ultragenyx Pharmaceutical je -43.61%
- Hodnota metriky Návratnost kapitálu společnosti Albireo Pharma Inc je -43.59%
- Hodnota metriky Návratnost kapitálu společnosti e-Play Digital je -43.44%
- Hodnota metriky Návratnost kapitálu společnosti e-Therapeutics Plc je -43.43%
- Hodnota metriky Návratnost kapitálu společnosti Western Metallica Resources Cor je -43.42%
- Hodnota metriky Návratnost kapitálu společnosti Petros Pharmaceuticals je -43.21%
- Hodnota metriky Návratnost kapitálu společnosti European Assets Trust Plc je -43.17%
- Hodnota metriky Návratnost kapitálu společnosti StartEngine Crowdfunding je -43.17%